Respiratory syncytial virus vaccine development.

摘要: Abstract The importance of RSV as a respiratory pathogen in young children made it priority for vaccine development shortly after was discovered. Unfortunately, over 50 years no has yet been licensed and is not certain which if any vaccines being developed will be successful. first candidate vaccine, formalin inactivated (FI-RSV), tested the 1960s predisposed recipients to more serious disease with later natural infection. ongoing challenges developing are balanced by advances our understanding virus, host immune response infection, pathogenesis disease. It seems likely that efficient appropriately focused effort safe effective within reach. There at least 4 different target populations an i.e. naive infant, infant >4–6 months age, pregnant women, elderly adults. Each population issues related development. Numerous from live attenuated virus like particle have evaluated animals. Very few studied humans studies needed determine worth moving toward licensure. Some changes approach may improve efficiency evaluating vaccines. complexity suggests collaboration among academic, government, funding institutions industry most efficiently achieve vaccine.